ClinicalTrials.gg
CompletedNCT00523419Updated Jun 28, 2011Results posted

Chemotherapy for Patients With Osteosarcoma

A Phase 2 interventional study of Pemetrexed in Osteosarcoma, sponsored by Eli Lilly and Company. Completed at 13 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-06-28.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies in Osteosarcoma with a site in France — 7 open to participants now, 13 under way, 2 of them phase 3. Osteosarcoma · France.

Enrollment
26th of 30
32 · median 91
Started
2007
with 1 other
Phase 2
12 of 36
2 open now
Registered
6th of 36
by date
Lead sponsor
2 of 36
Eli Lilly and Company

Among the 36 studies in Osteosarcoma with a site in France, this one is the 26th largest by enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2007, is one of 12 in phase 2, and was the 6th registered.

Osteosarcoma

488 studies on the registry are indexed under Osteosarcoma; 123 are open to participants now.

Browse Osteosarcoma studies →

Open to participants now

7 of the 36 studies in Osteosarcoma with a site in France are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 100 Osteosarcoma studies recruiting now, 41 (41%) set no upper age limit and 55 (55%) stop at 75 or younger; 75 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Osteosarcoma with a site in France, or all of them as a file.
02

Study summary

The primary purpose of your participation in this study is to help answer the following research questions, and not to provide you treatment for your condition.

  • To assess how well treatment with pemetrexed works for patients with your type of cancer
  • To assess for any side effects that might be associated with pemetrexed.
  • To look at the characteristics and levels of certain of your genes and proteins to learn more about osteosarcoma and how pemetrexed works in your body.
03

Conditions studied

  • Osteosarcoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological diagnosis of high grade locally advanced or osteosarcoma
  • Must have one prior chemotherapy regimen for advanced disease
  • At least 1 unidimensional by computed tomography (CT) scan
  • Have a good performance status
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Have a serious concomitant systemic disorder (for example active infection)
  • Have not adequately treated
  • Significant weight loss (that is more than 20%) over the previous 6 weeks before study entry
  • Inability or unwillingness to take folic acid or vitamin B12 supplementation and
  • Pregnant or breast-feeding
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Pemetrexed

    Participants received pemetrexed 500 milligrams per square meter (mg/m\^2) by intravenous (IV) infusion of 10 minutes on Day 1 of each 21-day cycle.

    Drug: Pemetrexed

Interventions

  • 500 mg/m\^2, IV every 21 days until disease progression, unacceptable toxicity, participant or physician's decision.

    Also known as: LY231514, Alimta

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Tumor Response

    Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR) = disappearance of all target lesions; Partial Response (PR) = at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) = at least a 20% increase in sum of longest diameter of target lesions; Stable Disease (SD) = small changes that do not meet above criteria. Tumor Response Rate(%) = sum of number of PR + CR observed/number of participants qualified for tumor response analysis \* 100.

    Time frame: Baseline to 21 months

Secondary outcomes

  1. Time to Treatment Failure

    When the protocol was written, time to treatment failure (TTTF) was included as a secondary endpoint. However, it was subsequently realized that due to the design of the study, participants are treated until disease progression or discontinuation from study treatment, not for a fixed number of cycles. Therefore, it was concluded that analysis of TTTF was inappropriate with the current study design and the analysis was not conducted, since it would be essentially the same as Progression-Free Survival.

    Time frame: Baseline to 21 months

  2. Correlation of Disease Outcome With Pharmacogenomic Analysis

    It was planned to examine methylthioadenosine phosphorylase (MTAP) gene deletion, folate receptor alpha (FRα) and folylpoly-gamma-glutamate synthetase (FPGS) expression, and to correlate the results with the clinical data to determine the association between these factors and clinical outcome to treatment. However, due to the small number of participants with partial response (n=1), the planned statistical analyses that would correlate responders/non responders with pharmacogenomics data are no longer valid and the analyses were not conducted.

    Time frame: Baseline to 21 months

  3. Number of Participants With Adverse Events (Pharmacology Toxicity)

    Pharmacology toxicity was defined as serious and non-serious adverse events. Summaries of these adverse events are located in the Reported Adverse Event Section.

    Time frame: Baseline to 21 months

  4. Duration of Response

    The duration of a complete response (CR) or partial response (PR) was defined as the time from the first objective status assessment of CR or PR to the first date of progression or death as a result of any cause: CR was achieved if all tumor lesions disappeared; PR was achieved if there was \>=30% decrease in sum of the longest diameter (LD) of target lesions (reference: baseline sum LDs) or complete disappearance of target lesions with persistence (but not worsening) of \>=1 nontarget lesions and no appearance of new lesions.

    Time frame: Baseline to 31 months

  5. Progression-Free Survival (PFS)

    PFS was from date of study enrollment to first date of objectively determined progressive disease (PD) or death from any cause. For participants who did not die as of data cut-off date and who did not have objective PD, PFS was censored at date of last objective progression-free disease assessment. For participants who received subsequent systemic anticancer therapy (after discontinuation from study drug) before objectively determined disease progression or death, PFS was censored at date of last objective progression-free disease assessment, before post-discontinuation chemotherapy.

    Time frame: Baseline to 10.4 months

  6. Overall Survival (OS) Time

    OS was the duration from enrollment to death. For participants who lived, OS was censored at the last contact.

    Time frame: Baseline to 27.6 months

07

Results

Posted Sep 21, 2010

Participant flow

Participant flow — Overall Study
MilestonePemetrexed
Started32
Completed0
Not completed32
Withdrew: Adverse event1
Withdrew: Withdrawal by subject1
Withdrew: Physician decision2
Withdrew: Progressive disease22
Withdrew: Death due to study disease4
Withdrew: Death due to adverse event2

Outcome measures

PrimaryPercentage of Participants With Tumor Response

Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR) = disappearance of all target lesions; Partial Response (PR) = at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) = at least a 20% increase in sum of longest diameter of target lesions; Stable Disease (SD) = small changes that do not meet above criteria. Tumor Response Rate(%) = sum of number of PR + CR observed/number of participants qualified for tumor response analysis \* 100.

Time frame:
Baseline to 21 months
Reported as:
Number · percentage of participants
Percentage of Participants With Tumor Response
percentage of participantsPemetrexed
Response Rate3.1 (0.1 to 16.2)
Complete Response (CR)0 (0 to 0)
Partial Response (PR)3.1 (0.1 to 16.2)
Stable Disease (SD)15.6 (5.3 to 32.8)
Progressive Disease (PD)68.8 (50.0 to 83.9)
Unknown12.5 (3.5 to 29.0)
SecondaryTime to Treatment Failure

When the protocol was written, time to treatment failure (TTTF) was included as a secondary endpoint. However, it was subsequently realized that due to the design of the study, participants are treated until disease progression or discontinuation from study treatment, not for a fixed number of cycles. Therefore, it was concluded that analysis of TTTF was inappropriate with the current study design and the analysis was not conducted, since it would be essentially the same as Progression-Free Survival.

Time frame:
Baseline to 21 months
Reported as:
Mean · days

No measurements were reported for this outcome.

SecondaryCorrelation of Disease Outcome With Pharmacogenomic Analysis

It was planned to examine methylthioadenosine phosphorylase (MTAP) gene deletion, folate receptor alpha (FRα) and folylpoly-gamma-glutamate synthetase (FPGS) expression, and to correlate the results with the clinical data to determine the association between these factors and clinical outcome to treatment. However, due to the small number of participants with partial response (n=1), the planned statistical analyses that would correlate responders/non responders with pharmacogenomics data are no longer valid and the analyses were not conducted.

Time frame:
Baseline to 21 months
Reported as:
Number · correlation coefficient

No measurements were reported for this outcome.

SecondaryNumber of Participants With Adverse Events (Pharmacology Toxicity)

Pharmacology toxicity was defined as serious and non-serious adverse events. Summaries of these adverse events are located in the Reported Adverse Event Section.

Time frame:
Baseline to 21 months
Reported as:
Number · participants
Number of Participants With Adverse Events (Pharmacology Toxicity)
participantsPemetrexed
Serious Adverse Events11
All Other Nonserious Adverse Events26
SecondaryDuration of Response

The duration of a complete response (CR) or partial response (PR) was defined as the time from the first objective status assessment of CR or PR to the first date of progression or death as a result of any cause: CR was achieved if all tumor lesions disappeared; PR was achieved if there was \>=30% decrease in sum of the longest diameter (LD) of target lesions (reference: baseline sum LDs) or complete disappearance of target lesions with persistence (but not worsening) of \>=1 nontarget lesions and no appearance of new lesions.

Time frame:
Baseline to 31 months
Reported as:
Number · months
Duration of Response
monthsPemetrexed
Duration of Response9.5 (4.0 to NA)
SecondaryProgression-Free Survival (PFS)

PFS was from date of study enrollment to first date of objectively determined progressive disease (PD) or death from any cause. For participants who did not die as of data cut-off date and who did not have objective PD, PFS was censored at date of last objective progression-free disease assessment. For participants who received subsequent systemic anticancer therapy (after discontinuation from study drug) before objectively determined disease progression or death, PFS was censored at date of last objective progression-free disease assessment, before post-discontinuation chemotherapy.

Time frame:
Baseline to 10.4 months
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsPemetrexed
Progression-Free Survival (PFS)1.4 (1.4 to 1.7)
SecondaryOverall Survival (OS) Time

OS was the duration from enrollment to death. For participants who lived, OS was censored at the last contact.

Time frame:
Baseline to 27.6 months
Reported as:
Median · months
Overall Survival (OS) Time
monthsPemetrexed
Overall Survival (OS) Time5.5 (2.3 to 10.5)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed—11/32 (34.4%)26/32 (81.3%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventPemetrexed
Pericardial effusionCardiac disorders2/32
Febrile bone marrow aplasiaBlood and lymphatic system disorders1/32
Febrile neutropeniaBlood and lymphatic system disorders1/32
ThrombocytopeniaBlood and lymphatic system disorders1/32
General physical health deteriorationGeneral disorders1/32
PyrexiaGeneral disorders1/32
Sudden deathGeneral disorders1/32
Catheter related infectionInfections and infestations1/32
SepsisInfections and infestations1/32
Staphylococcal infectionInfections and infestations1/32
Most frequent other events
Showing 10 of 29
Most frequent other events
EventPemetrexed
AstheniaGeneral disorders8/32
Alanine aminotransferase increasedInvestigations7/32
AnaemiaBlood and lymphatic system disorders6/32
ConstipationGastrointestinal disorders5/32
NauseaGastrointestinal disorders4/32
FatigueGeneral disorders4/32
Oedema peripheralGeneral disorders4/32
Aspartate aminotransferase increasedInvestigations4/32
CoughRespiratory, thoracic and mediastinal disorders4/32
ErythemaSkin and subcutaneous tissue disorders4/32

Baseline characteristics

Age Continuous
Age Continuous(years)Pemetrexed
Mean42.1 ± 16.28
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed
Female12
Male20
Region of Enrollment
Region of Enrollment(participants)Pemetrexed
France13
Spain3
Germany6
United Kingdom1
Italy9
Best Response of Last Prior Treatment Regimen for Osteosarcoma
Best Response of Last Prior Treatment Regimen for Osteosarcoma(participants)Pemetrexed
Complete Response1
Partial Response3
Stable Disease10
Progressive Disease15
Not Applicable3
Eastern Cooperative Oncology Group (ECOG) performance status
Eastern Cooperative Oncology Group (ECOG) performance status(participants)Pemetrexed
ECOG Performance Status 016
ECOG Performance Status 114
ECOG Performance Status 21
ECOG Performance Status Not Available1
Histopathological Diagnosis of Osteosarcoma at Study Entry
Histopathological Diagnosis of Osteosarcoma at Study Entry(participants)Pemetrexed
Number32
Number of Target Lesions
Number of Target Lesions(participants)Pemetrexed
0 Target Lesions1
1 Target Lesion9
2 Target Lesions8
3 Target Lesions4
4 Target Lesions3
5 Target Lesions7
Number of non target lesions
Number of non target lesions(participants)Pemetrexed
0 Non Target Lesions10
1 Non Target Lesion15
2 Non Target Lesions5
3 Non Target Lesions1
5 Non Target Lesions1

2 further baseline measures are reported on the registry.

08

Study locations

13 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bordeaux, 33076, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lyon, 69437, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Marseille, 13385, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Villejuif, 94805, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Heidelberg, 69120, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Munich, 81377, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bologna, 40136, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Milano, 20133, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Torino, 1053, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 08025, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28050, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pamplona, 31008, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Newcastle-Upon-Tyne, Tyneside NE4 6BE, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Jun 2009 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2010, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2007
First posted
Aug 31, 2007
Start
Sep 2007
Primary completionActual
Jun 2009
CompletionActual
Jun 2010
Results first posted
Sep 21, 2010
Last update
Jun 28, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00523419
First posted
Aug 31, 2007
Start date
Sep 2007
Primary completion
Jun 2009
Completion
Jun 2010
Results posted
Sep 21, 2010
Last update
Jun 28, 2011

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemetrexed

Start the discussion